May 10 |
Kiora Pharmaceuticals GAAP EPS of $0.38, revenue of $16M
|
May 10 |
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
|
May 8 |
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
|
May 6 |
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa
|
Apr 11 |
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
|
Apr 5 |
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
|